Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Sell
27
MLTX Quote, Financials, Valuation and Earnings
Last price:
$39.59
Seasonality move
:
-6.98%
Day range:
$37.70 - $39.98
52-week range:
$36.52 - $58.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.48x
Volume:
568.7K
Avg. volume:
332.5K
1-year change:
-18.16%
Market cap:
$2.4B
Revenue:
--
EPS (TTM):
-$1.89
Earnings Data
Next earnings date for MLTX
May 07
2025
Most recent earnings per share
-$0.72
Missed by $0.13
(Feb 26/2025)
Consensus Estimate
-$0.59
(Feb 26/2025)
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
MLTX Quarterly Earnings History
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 05/07/2025 | Q1 | -- | -- | -- | -$0.76 | -- |
| 02/26/2025 | Q4 | -- | -- | -$0.72 | -$0.59 | -$0.13 |
| 11/07/2024 | Q3 | -- | -- | -$0.56 | -$0.45 | -$0.11 |
| 08/07/2024 | Q2 | -- | -- | -$0.39 | -$0.28 | -$0.11 |
| 05/07/2024 | Q1 | -- | -- | -$0.22 | -$0.21 | -$0.01 |
| 02/29/2024 | Q4 | -- | -- | -$0.10 | -$0.27 | $0.17 |
| 11/14/2023 | Q3 | -- | -- | -$0.18 | -$0.25 | $0.07 |
| 08/10/2023 | Q2 | -- | -- | -$0.23 | -$0.29 | $0.06 |
| 05/11/2023 | Q1 | -- | -- | -$0.23 | -$0.29 | $0.06 |
| 03/20/2023 | Q4 | -- | -- | -$0.31 | -$0.28 | -$0.03 |
| 11/14/2022 | Q3 | -- | -- | -$0.27 | -- | -- |
| 08/12/2022 | Q2 | -- | -- | -$0.34 | -- | -- |
| 03/31/2022 | Q1 | -- | -- | -$0.43 | -- | -- |
| 09/30/2021 | Q3 | -- | -- | -$0.17 | -- | -- |
| 06/30/2021 | Q2 | -- | -- | -$0.89 | -- | -- |
MoonLake Immunotherapeutics Earnings Questions
-
How Much did MoonLake Immunotherapeutics Generate in Revenue Last Quarter?
MoonLake Immunotherapeutics reported -- worth of top line sales in its most recent quarter.
-
Did MoonLake Immunotherapeutics Beat Earnings Last Quarter?
MoonLake Immunotherapeutics announced earnings per share of -$0.72 which represents a miss of analyst forecast a -$0.59 per share.
-
Is MoonLake Immunotherapeutics Profitable?
MoonLake Immunotherapeutics reported -- that represents -- per share over the last quarter.
-
What is the Analyst Consensus for MoonLake Immunotherapeutics EPS Next Year?
MoonLake Immunotherapeutics's earnings are forecast to decrease from -$1.89 per share to -$1.72 per share next year representing a decrease of -66.19%.
-
When is MoonLake Immunotherapeutics's Earnings Date?
MoonLake Immunotherapeutics's next earnings date is May 7, 2025.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 18
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
